4 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 90 points (0.6%) at 15,153 as of Tuesday, Sept. 10, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,842 issues advancing vs. 1,092 declining with 95 unchanged.

The Drugs industry currently sits up 0.3% versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the industry include Vertex Pharmaceuticals ( VRTX), down 2.4%, and Biomarin Pharmaceutical ( BMRN), down 2.2%. A company within the industry that increased today was Sanofi ( SNY), up 1.4%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Neurocrine Biosciences ( NBIX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Neurocrine Biosciences is down $4.93 (-29.5%) to $11.77 on heavy volume. Thus far, 6.6 million shares of Neurocrine Biosciences exchanged hands as compared to its average daily volume of 595,100 shares. The stock has ranged in price between $11.31-$12.17 after having opened the day at $12.05 as compared to the previous trading day's close of $16.70.

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Neurocrine Biosciences has a market cap of $1.1 billion and is part of the health care sector. Shares are up 115.4% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Neurocrine Biosciences a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Neurocrine Biosciences as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Neurocrine Biosciences Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Movers: Inovio, Neurocrine, Alnylam

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Wall Street Closes Lower Amid Continued Global Worries